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Background: Mitochondrial diseases due to deficiencies in the mitochondrial oxidative
phosphorylation system (OXPHOS) can be associated with nuclear genes involved
in mitochondrial translation, causing heterogeneous early onset and often fatal
phenotypes.
Case report: The authors describe the clinical features and diagnostic workup of
an infant who presented with an early onset severe encephalopathy, spastic-dystonic
tetraparesis, failure to thrive, seizures and persistent lactic acidemia. Brain imaging
revealed thinning of the corpus callosum and diffuse alteration of white matter signal.
Genetic investigation confirmed two novel mutations in the GFM1 gene, encoding
the mitochondrial translation elongation factor G1 (mtEFG1), resulting in combined
deficiencies of OXPHOS.
Discussion: The patient shares multiple clinical, laboratory and radiological similarities
with the 11 reported patients with mutations involving this gene, but presents with
a stable clinical course without metabolic decompensations, rather than a rapidly
progressive fatal course. Defects inGFM1 gene confer high susceptibility to neurologic or
hepatic dysfunction and this is, to the best of our knowledge, the first described patient
who has survived beyond early childhood. Reporting of such cases is essential so as
to delineate the key clinical and neuroradiological features of this disease and provide a
more comprehensive view of its prognosis.
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Introduction
Mitochondrial diseases due to deficiencies in the mitochondrial
oxidative phosphorylation system (OXPHOS) have an estimated
birth prevalence of 1 in 10,000 (Schaefer et al., 2008). Mito-
chondria are semi-autonomous organelles. They contain their
own genome (mtDNA), but rely on the nuclear DNA for full
functionality. The nuclear genome encodes approximately 1500
mitochondrial proteins (Elstner et al., 2008) and provides essen-
tial factors for mtDNA replication, transcription, translation, and
assembly of the five OXPHOS complexes. Human mtDNA is a
minimal genome and encodes only 13 essential subunits of the
OXPHOS system as well as 2 rRNAs and 22 tRNAs (Anderson
et al., 1981). Mitochondria possess their own translation system
to synthesize the mtDNA-encoded proteins. With the exception
of complex II, all OXPHOS enzymes derive from dual genetic
origin with at least one subunit encoded by the mtDNA, thus,
mitochondrial protein synthesis is crucial for OXPHOS func-
tion and ATP generation. It is therefore not surprising, that
defects in the mitochondrial translation machinery are an emerg-
ing and increasingly recognized group of mitochondrial disor-
ders (Jacobs and Turnbull, 2005; Scaglia and Wong, 2008; Smits
et al., 2010; Kemp et al., 2011). Defects in mitochondrial protein
translation are hypothesized to be the primary cause of com-
bined OXPHOS deficiencies, in which the activity of more than
one OXPHOS complex is compromised (Smits et al., 2010; Kemp
et al., 2011; Rotig, 2011). New sequencing technologies have
rapidly increased the canon of genes known to cause combined
respiratory chain deficiency, an effect largely exerted through dis-
ruptedmitochondrial DNAmaintenance, nucleotide transport or
various aspects of translation including tRNA modification and
aminoacylation (Taylor et al., 2014).
The early genetic investigation involving patients with defec-
tive mitochondrial translation led to the description of a number
of nuclear-encoded defects in initiation, elongation, and termi-
nation factors required for mitochondrial translation (Ylikallio
and Suomalainen, 2012). These seem to be responsible for hetero-
geneous phenotypes, manifesting predominantly in tissues with
high energy requirements and with early onset and rapidly pro-
gressive fatal courses (Antonicka et al., 2006; Balasubramaniam
et al., 2012).
Here we describe the clinical features and diagnostic
workup of an infant who presented with an early onset
severe encephalopathy resulting from combined deficiencies of
OXPHOS due to recessive mutations (including one novel vari-
ant) in a nuclear gene (GFM1), encoding mitochondrial transla-
tion elongation factor G1 (mtEFG1) and compare these findings
with other reported cases.
Background
Case Report
This female patient (Figure 1A), currently 5 years 6 months old,
was born to unrelated Caucasian parents following a pregnancy
that was uneventful until 36 weeks gestation, when acute oligohy-
dramnios and late presenting breech were diagnosed. Cesarean
section was performed without complication and no neonatal
resuscitation was required. Birth weight was on the 50th cen-
tile, length on the 10th and head circumference on the 97th
centile. Neonatal metabolic and hearing screenings were nor-
mal. At 2 months old, she developed paroxysms of irritability
that evolved into a persistently irritable state with inconsolable
crying, opisthotonic posturing, feeding difficulties, and failure
to thrive. At presentation, she had severe axial hypotonia with
poor head control, spasticity of extremities and severely impaired
visual tracking; there were no noticeable dysmorphic features.
At 7 months old, she was already developmentally delayed prior
to the onset of infantile spasms, which showed prompt clini-
cal resolution with medication, although electrical abnormalities
persisted on the electroencephalogram. She gained eye contact
and social smile, but has never been able to sit independently
and has not acquired verbal language skills. She has developed a
FIGURE 1 | Brain magnetic resonance imaging. (A) Photograph of the
patient aged 5 years demonstrating left convergent squint and normal facial
appearance. (B) Axial T2-weighted image at 29 months, revealing enlarged
lateral ventricles. (C) Coronal T2-FLAIR image at 29 months, displaying
abnormal white matter signal in a periventricular distribution. (D) Midsagittal
T1-FLAIR image at 29 months, showing thinning of the corpus callosum with
enlarged subarachnoid spaces. (E) Coronal T2-FLAIR image at 5 years 6
months, showing abnormal periatrial signal and enlarged lateral ventricles. (F)
Axial 3D FSPGR image at 5 years 6 months, displaying abnormal signal in the
posterolateral region of the putamen nucleus.
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spastic-dystonic tetraparesis with dystonic movements affecting
her face, particularly her mouth.
After excluding perinatal metabolic and infectious causes, fur-
ther investigation confirmed persistently elevated lactate levels in
blood (maximum 4.87mmol/L; normal range 0.77–2.44mmol/L)
and cerebral spinal fluid (CSF; 4.79mmol/L; normal range
1.11–2.22mmol/L), along with elevated blood pyruvate (maxi-
mum 0.15mmol/L; normal range 0.03–0.10mmol/L) and alanine
(maximum 742 umol/L; normal range 226–416 umol/L). There
was no hepatic dysfunction. The remaining blood, CSF and urine
analysis were unremarkable.
Brain magnetic resonance revealed widened subarachnoid
spaces, Sylvian sulcus and ventricular system; diffuse and non-
specific alteration of white matter signal and thinning of the cor-
pus callosum (Figures 1B–D). These findings were only slowly
progressive and apparently unchanged on repeat cranial MR
imaging at 16 and 29 months old. Spectroscopy showed no sig-
nificant changes for age, including lactate. However, repeat MRI
performed at 5 years 6 months old did show some further ven-
tricular enlargement (Figure 1E) and abnormal signal change in
the posterolateral putamen (Figure 1F).
Electroencephalography showed a poorly formed background
with multifocal polyspike paroxysms. Visual evoked potentials
revealed delayed conduction and brainstem auditory evoked
potentials indicated bilateral vestibulocochlear nerve involve-
ment. Electromyography demonstrated discrete involvement of
the lower limb motor axons without demyelination. Muscle and
skin biopsies were performed to investigate a likely mitochon-
drial disorder.
Materials and Methods
All procedures followed were in accordance with the ethical stan-
dards of the responsible committee on human experimentation
(institutional and national) and with the Helsinki Declaration of
1975, as revised in 2000. Informed consent was obtained from the
parents of the patient, including consent about the publication of
identifying information.
Histopathological and Biochemical Studies
A diagnostic muscle biopsy (quadriceps) was orientated, frozen
and processed for histology and histochemistry following stan-
dard procedures. Respiratory chain complex activities were
measured and normalized to citrate synthase activity in
cultured fibroblasts as previously described (Kirby et al.,
2007).
Genetic Studies
Mitochondrial DNA analysis
Real-time PCR analysis of mtDNA levels was undertaken in mus-
cle DNA to investigate a possible mtDNA depletion syndrome.
Southern blot analysis of mtDNA linearized following PvuII
digestion was performed using a probe obtained by amplification
of a region of the human MT-RNR1 gene, whilst mtDNA rear-
rangements were also screened by long-range PCR. The sequence
of the entire mitochondrial genome was determined in muscle
using standard protocols.
Next generation sequencing of nuclear-mitochondrial
genes
Simultaneous sequencing of the coding regions (exons and exon-
intron junctions) of 150 nuclear-encoded genes associated with
mitochondrial respiratory chain defects was performed using
next generation sequencing technology consisting of an in-
solution hybridization enrichment method with a custom Sure
Select XT kit (Agilent Technologies) and subsequent sequencing
in MiSeq platform (Illumina).
The custom Sure Select oligonucleotide probe library was
designed including all transcripts from each target gene.
Sequence capture, enrichment, and elution were performed
according to the manufacturer’s instructions. Captured frag-
ments were sequenced in pair-end 100-base mode using
Miseq (Illumina) platform. Image analysis and process-
ing of the fluorescence intensities in sequences (“Base
Calling”) was performed with Real Time Analysis (RTA)
software 1.8.70 (Illumina), and quality control of the data
was developed with FastQC v0.10.1 program (http://www.
bioinformatics.bbsrc.ac.uk/projects/fastqc/). Reads were
aligned to the reference genome GRCh37 with BWA
v0.7.5a software (Li and Durbin, 2009). NGSrich v0.7.5
software (http://ngsrich.sourceforge.net) used as a con-
trol previous to variant detection, and BEDTools 2.17.0
(http://bedtools.readthedocs.org/en/latest/#) and Picard 1.93
(http://picard.sourceforge.net) for intermediate steps. Varscan
and SAMtools v0.1.19 (Li et al., 2009) were the variant detection
software used and Annovar Nov2011 (Wang et al., 2010) for
variant annotation. The assay reached a mean coverage for the
GFM1 gene of 240X and 313X for exons 12 and 16 respectively.
Sanger sequencing was used to confirm the mutations iden-
tified in the proband and determine phase. Exons 12 and 16 of
GFM1 gene (NM_024996) were amplified with specific primers
designed using the free software Primer3 v.0.4.0 (www.frodo.wi.
mit.edu/) and the amplified fragments sequenced using standard
methodologies. Sequencing reactions consisted of 1.0µl of previ-
ously purified PCR products (ExoSAP-IT, USB, Cleveland, OH),
1µl of each primer, and 1µl of Big Dye Terminator v3.1 from
the Cycle Sequencing kit (Applied Biosystems, Foster City, CA).
The reactions were run on an ABI 3730 DNA Analyzer (Applied
Biosystems, Foster City, CA). Analysis was performed with the
Staden package free software.
Cell Preparation and Western Blot Analysis
Human fibroblasts were trypsinized, pelleted and resuspended in
cell lysis buffer [50mM Tris-HCl pH 7.5, 130mM NaCl, 2mM
MgCl2, 1% Nonidet P-40, 1mM PMSF and protease inhibitor
cocktail (Roche)]. Cell lysates were vortexed briefly, centrifuged
at 500 g for 5min at 4◦C and the supernatant retained.
Mitochondrial fractions were prepared from cell pellets resus-
pended in homogenization buffer (0.6M mannitol, 10mM Tris-
HCl pH7.4, 1mM EGTA, 0.1% BSA, and 1mM PMSF) and hand
homogenized by 15 passes in a Teflon:glass dounce homogenizer.
Following centrifugation at 400 g the supernatant was retained
and the pellet was re-homogenized and centrifuged as before. The
combined supernatants were cleared at 400 g and then the crude
mitochondria pelleted at 11,000 g.
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Cell lysates and mitochondrial lysates were incubated
with sample dissociation buffer (final concentrations: 6.25mM
Tris/HCl pH 6.8, 2% SDS, 10% glycerol 0.01% bromophenol blue
and100mM DTT) for 30min at 37◦C, separated by 12% SDS–
PAGE and immobilized by wet transfer (100V, 1 h at 4◦C) on
to PVDF membrane (Immobilon-P, Millipore Corporation) in
25mM Tris, 192mM glycine, 0.02% SDS, and 15% methanol.
Proteins of interest were bound by overnight incubation at 4◦C
with antibodies against COXI (Abcam ab14705), SDHA (Abcam
ab14715), Porin/VDAC1 (Abcam ab14734), mtEFG1 (Abcam
ab173529), and NDUFB8 (Abcam ab110242) followed by HRP-
conjugated secondary antibodies (Dako Cytomation) and visual-
ized using ECL-prime (GE Healthcare) and BioRad ChemiDoc
MP with Image Lab software.
De novo Mitochondrial Protein Synthesis
Mitochondrial protein synthesis in cultured cells was performed
essentially as described previously (Chomyn, 1996). Fibroblasts
were labeled for 1 h in methionine/cysteine free DMEM (Sigma)
with 200 uCi/ml of a [35S]-methionine/cysteine mixture (Perkin
Elmer) and 100 ug/ml emetine dihydrochloride (Sigma) followed
by 10min chase in standard DMEM with additional 7.5 ug/ml
cold methionine. Aliquots (50 ug) of total cell protein were
separated by 15% SDS–PAGE. Signals were detected using the
Typhoon FLA9500 Phosphorimager and ImageQuant software
(GE Healthcare).
Genetic, Pathological, and Biochemical Results
Genetic studies were performed sequentially in accordance
with clinical suspicion and showed a 46, XX normal kary-
otype, fluorescent in situ hybridization (FISH) excluded
Wolf-Hirschhorn syndrome, direct sequencing of the
FOXG1 gene was normal, multiplex ligation-dependent
probe amplification (MLPA) for subtelomeric deletions
and for CDKL5, NTNG1, and ARX genes was unremark-
able. The activity of pyruvate dehydrogenase was normal in
fibroblasts.
Muscle histology and histochemistry showed no evidence of
obvious subsarcolemmal mitochondrial accumulation (ragged-
red fibers) or inclusions and mild variation in fiber size
(Figure 2A). There was a generalized decrease in histochemi-
cal cytochrome c oxidase (COX) activity including a popula-
tion of fibers (mosaic) that were COX-deficient (Figure 2B). The
succinate dehydrogenase (SDH) reaction showed a population
of pale fibers (Figure 2C), whereas the sequential COX/SDH
reaction highlighted a population of weakly-reacting blue (COX-
deficient) fibers (Figure 2D). In addition, the size of intracel-
lular lipid droplets stained with Sudan Black appeared to be
increased (not shown). Biochemical assessment of respiratory
chain enzymatic function in fibroblasts confirmed impaired com-
plex I (0.019 units; controls (mean ± SD) 0.197 ± 0.034), com-
plex III (0.211 units; controls (mean ± SD) 0.646 ± 0.192),
and complex IV (0.165 units; controls (mean ± SD) 1.083 ±
0.186) activities, with a low complex I:II ratio (0.071; range
0.58–0.90) consistent with a generalized defect of mitochon-
drial translation (Figure 2E). The activity of complex V was not
assessed.
Mitochondrial DNA copy number abnormalities and large-
scale rearrangements were excluded in muscle; complete
sequencing of the mitochondrial genome in this tissue identified
several well-characterized polymorphic variants, but no plausible
pathogenic mtDNA mutation.
FIGURE 2 | Muscle histology and histochemistry reveals
mitochondrial abnormalities. (A) Haematoxylin and Eosin (H&E)
histology shows mild variation in fiber size. (B) Cytochrome c oxidase
(COX) histocytochemical activity revealed a mosaic pattern of COX
deficiency without subsarcolemmal mitochondrial aggregates. (C)
Succinate dehydrogenase (SDH) reaction indicates a population of pale
fibers within the section. (D) Sequential COX-SDH histochemistry shows a
population of weak “blue” fibers corresponding to the COX-deficient,
SDH-positive fibers detected following the individual enzyme reactions. (E)
The assessment of individual respiratory chain enzyme activities in
fibroblasts identified a severe OXPHOS deficiency affecting complex I, III,
and IV in the patient (blue) compared with controls (red). Mean enzyme
activities of control fibroblasts (n = 8) are set at 100% and error bars
represent the standard deviation. *denotes values outside of the normal
range. (F) Pedigree and sequence analysis of the two mutations identified
in the patient.
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Skeletal muscle DNA was used to perform genetic screen-
ing for mitochondrial encephalopathy, with simultaneous next
generation sequencing of the coding regions of 150 genes asso-
ciated with mitochondrial respiratory chain disorders. This
revealed two inherited, likely pathogenic heterozygous muta-
tions: c.1404delA, p.(Gly469Valfs∗84), in exon 12 (NM_024996.5,
OMIM 606639) and c.2011C>T, p.(Arg671Cys), in exon 16
(NM_024996.5, OMIM 606639) of the GFM1 gene (Figure 2F).
The former predicts a novel frameshift mutation, whilst the lat-
ter is a reported missense mutation predicting the substitution
p.(Arg671Cys) of a conserved amino acid (Calvo et al., 2012;
Galmiche et al., 2012). Further analysis verified that the mother
was a heterozygous carrier of the c.1404delA p.(Gly469Valfs∗84)
variant whereas the father was a heterozygous carrier of the
c.2011C>T p.(Arg671Cys) variant.
Western blot analysis showed that steady state levels of
mtEFG1 protein were severely decreased in isolated mitochon-
dria from patient fibroblasts (Figure 3A) compared to control
fibroblasts, confirming pathogenicity of the GFM1 mutations.
Western blot analysis of patient fibroblasts showed a reduction in
the steady-state levels of NDUFB8 (complex I subunit) and COXI
(complex IV subunit), but similar levels of SHDA (complex II)
compared to controls (Figure 3B), which corresponds well with
the complex activity data (Figure 2E). A generalized impairment
of de novo mitochondrial protein synthesis was also observed
in patient fibroblasts (Figure 3C), consistent with a decrease in
translation elongation due to the reduction of mtEFG1 protein
levels.
Discussion
The nuclear gene, GFM1, is located at 3q25.1–q26.2 and encodes
the mitochondrial translation factor mtEFG1 (Gao et al., 2001),
which acts as a five domain GTPase (Valente et al., 2007; Balasub-
ramaniam et al., 2012). It catalyzes the translocation of peptidyl-
tRNA from the ribosomal acceptor aminoacyl site to the peptidyl
site following peptide bond formation, with the concomitant
removal of the deacylated tRNA, advancement of the mRNA by
one codon and exposure of the next codon (Smits et al., 2010).
Review of Similar Cases
Following the first report of recessive mutations in this gene
causing early-onset mitochondrial disease and a generalized dis-
order of mitochondrial translation (Coenen et al., 2004), 11 clin-
ical cases have been published in the literature (Coenen et al.,
2004; Antonicka et al., 2006; Valente et al., 2007; Smits et al., 2011;
Balasubramaniam et al., 2012; Calvo et al., 2012; Galmiche et al.,
FIGURE 3 | Biochemical assessment of patient fibroblasts. (A)
Mitochondria isolated from control (C1) and patient (P) fibroblasts were
subjected to SDS-PAGE and western blot analysis using an anti-mtEFG1
antibody. Anti-porin (VDAC1) antibody was used as a loading control. (B)
Whole cell lysate from control (C1 and C2) and patient (P) primary fibroblasts
were subjected to western blot analysis. Antibodies against COXI
(mitochondrial encoded subunit of Complex IV), NDUFB8 (nuclear encoded
subunit of Complex I), SDHA (nuclear encoded subunit of Complex II) and
porin/VDAC1 (mitochondrial loading control). (C) Control (C1 and C2) and
patient (P) fibroblasts were treated with emetine dihydrochloride to inhibit
cytosolic translation and mitochondrial protein synthesis analyzed by [35S]
met/cys incorporation (1 h followed by a 10min chase). Cell lysate (50µg)
was separated through a 15% polyacrylamide gel. The gel was stained with
Coomassie blue (CBB) to confirm equal loading. Post fixation and drying the
signal was visualized by Typhoon FLA9500 PhosphorImaging. Signals were
ascribed following established migration patterns (Chomyn, 1996).
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2012). A review of the clinical, laboratory and radiological char-
acteristics of the reported cases is shown in Table 1, highlighting
a number of similarities between our patient and those previously
characterized, although there are also some notable differences.
Similar to other described cases, our patient presented with
early-onset failure to thrive, as well as encephalopathy and ele-
vated blood lactate (Table 1). This latter biochemical finding was
the only feature persistently evident in all previous patients with
the exception of those reported by Calvo and colleagues who did
not mention biochemical findings (Calvo et al., 2012). Smits and
colleagues suggested that blood lactate levels correlated with dis-
ease severity (Smits et al., 2011), but this was not consistent in all
the patients described. Our patient showed a maximum plasma
lactate value of 4.87mmol/L with initial responsive acidosis,
whilst in other cases this ranged from 3.0 to 17mmol/L with some
children presenting with refractory fatal lactic acidemia.
Other common features were hypo- or hypertonia, develop-
mental delay, seizures in three cases (Valente et al., 2007; Smits
et al., 2011; Galmiche et al., 2012) and polyneuropathy (Galmiche
et al., 2012). The early onset, rapidly progressive and fatal clinical
course described in previously reported cases (Table 1) did not
unfold in the patient we present, contrary to the hypothesis of
Trivigno and Haerry (2011). In fact, having stabilized both clini-
cally and biochemically, she now maintains a reasonable quality
of life and shows no signs of imminent deterioration. However,
despite her apparent clinical stability, there is some neurora-
diological evidence that her condition continues to be slowly
progressive (Figures 1E–F).
Microcephaly and minor dysmorphic traits, though not
uncommon in early onset mitochondrial disease, are not
uniformly described in this condition. Common neurora-
diological features in the reported cases include corpus
TABLE 1 | Comparative study of clinical, laboratory and radiological findings of the patients reported with GFM1 mutations.
Clinical Reported cases
Features
Aa Ba Cb Db Ec Fd Ge Hf If Jg Kg Lh
Consanguinity + + − − − + − + + − − −
IUGR + + + + − + + + − na na −
Microcephaly + − + + + + + + + na na −
Dysmorphism − − + − + − + + + na na −
Feeding difficulties − − − na + + − + − na na +
Seizures − − − na + + − + − na + +
Delayed growth + + + na + − + − − + na +
Tonus disturbance + + − + + + + + + + + +
D. delay + + − na + + + + + na + +
Encephalopathy + + + na + + − + − + + +
Liver failure + + + + − − + − + na na −
Myopathy − − − − − − − + − na na −
Lactate ↑ + + + + + + + + + na na +
OXPHOS ↓ Fib IV, I,(III, V) I, IV I, IV,(III, V) IV,(I, III, V) I,(III−V) I, III, IV IV, (I) I, IV I, IV IV * I, III, IV
Mu I, IV − IV, V, (I) − I, (IV) III − IV IV IV * na
CNS CC + + + − − + − − na na na +
Findings WM + + − − + + + + na na na +
BG + − − − + − + + na na na +
BS − − − − + − − + na na na −
Age - onset 10d 7w 1d In utero 3w 2d 2d 1d 2d <1w <1y 2m
Age–death 27d 5m 9d <1d 16m 2y 8m 4y 20m na na -
aCoenen et al., 2004.
bAntonicka et al., 2006.
cValente et al., 2007.
dSmits et al., 2011.
eBalasubramaniam et al., 2012.
fGalmiche et al., 2012.
gCalvo et al., 2012.
hthis report.
*Described as “Combined OXPHOS deficiencies,” but respiratory chain enzyme analysis was only reported for liver cells (marked deficient complex I and IV activities).
BG, Basal Ganglia; BS, Brainstem; CC, Corpus Callosum; CNS, Central Nervous System; d, days; D, Developmental; Fib, Fibroblasts; IU, Intrauterine; m, months old; Mu, Muscle; na,
not applicable/not available; OXPHOS, Oxidative Phosphorylation; IUGR, intrauterine growth restriction; y, years old; w, weeks old; WM, White Matter; +, present; −, absent.
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callosum thinning, leukodystrophy and basal ganglia involve-
ment (Table 1), findings also identified in the patient we report.
Cardiac function was preserved in all patients. The detailed clini-
cal picture and outcome of the two unrelated patients mentioned
by Calvo and colleagues were not thouroughly described in their
report (Calvo et al., 2012), precluding a direct comparison at
present.
Our patient is compound heterozygous for a novel frameshift
mutation and a reported missense mutation, resulting in a
severe reduction in steady-state levels of mtEFG1 protein. The
c.1404delA, p.(Gly469Valfs∗84)mutation has not previously been
described, and introduces a premature termination codon into
the GFM1 transcript. Although not experimentally-confirmed,
this mutation is defined as pathogenic and is highly likely
to lead to nonsense-mediated mRNA decay. The c.2011C>T,
p.(Arg671Cys) pathogenic mutation has previously been iden-
tified in the homozygous state in a patient presenting with a
complex phenotype including severe encephalopathy and micro-
cephaly, severely decreased complex IV activity in muscle and
reduced activity of complexes I and IV in skin fibroblasts
(Galmiche et al., 2012) and as a heterozygous recessive muta-
tion by Calvo et al. (2012).Western blot analysis showedmtEFG1
protein reduced to <1% of control values in fibroblasts from
the patient and there was also a marked decrease in full assem-
bled complexes I, IV, and V compared to normal controls. The
c.1404delA, p.(Gly469Valfs∗84) and c.2011C>T, p.(Arg671Cys)
mutations therefore seem highly likely to be causative of our
patient’s clinical presentation andmultiple respiratory chain defi-
ciency, indicating a disorder of generalized mitochondrial trans-
lation. A comparison with the cases reported in the literature,
including two sibling pairs (Coenen et al., 2004; Antonicka et al.,
2006), shows all patients have inherited GFM1 mutations as
recessive Mendelian traits, with clear loss of function alleles
leading to mitochondrial translation defects with a combined
deficiency of OXPHOS components (Table 2). For all described
cases, OXPHOS anomalies were suspected histochemically by
decreased COX activity in muscle and the combined deficiency
of OXPHOS components and disorder of generalized mito-
chondrial translation was confirmed biochemically (Table 1).
Complex II activity was consistently spared and no quantita-
tive or qualitative mtDNA anomalies were found in the patients
(Galmiche et al., 2012).
Interestingly, the residual steady-state levels of mutated
mtEFG1 protein have been found to be higher in heart and
skeletal muscle than in liver and fibroblasts (Antonicka et al.,
2006), which might diminish the susceptibility of these tissues,
as has been observed in the published cases (Coenen et al., 2004;
Antonicka et al., 2006; Smits et al., 2011; Trivigno and Haerry,
2011). Reports suggest that the severity of the OXPHOS defects
due to GFM1 mutations correlates with the residual level of the
mutant protein in each tissue (Antonicka et al., 2006; Trivigno
and Haerry, 2011; Balasubramaniam et al., 2012). The differences
in residual protein levels are potentially due to diverse regulatory
and compensatory responses of the mitochondrial translation
system in different tissues that are currently not fully understood.
Indeed, altered expression of other translation elongation fac-
tors (mtEFTu and mtEFTs) has been previously demonstrated in
TABLE 2 | Summary of the mutations in GFM1 gene found in the reported
patients.
Reported GFM1 mutation Type of
cases mutation
Aa Homozygous c.521A>G p.(Asn174Ser) Missense
Ba Homozygous c.521A>G p.(Asn174Ser) Missense
Cb c.961T>C p.(Ser321Pro) +
c.1765-2_1765-1delAG p.(Gly589Profs*19)
Missense +
Frameshift
Db c. 961T>C p.(Ser321Pro) +
c.1765-2_1765-1delAG p.(Gly589Profs*19)
Missense +
Frameshift
Ec c.139C>T p.(Arg47*) + c.1487T>G
p.(Met496Arg)
Nonsense +
Missense
Fd Homozygous c.748C>T p.(Arg250Trp) Missense
Ge c.539delG p.(Gly180Alafs*11) +
c.688G>A p.(Gly230Ser)
Frameshift +
Missense
Hf Homozygous c.2011C>T p.(Arg671Cys) Missense
If Homozygous c.1193T>C
p.(Leu398Pro)
Missense
Jg c.720delT p.(Glu241Asnfs*2) +
c.2011C>T p.(Arg671Cys)
Frameshift +
Missense
Kg c.720delT p.(Glu241Asnfs*2) +
c.910A>G p.(Lys304Glu)
Frameshift +
Missense
Lh c.1404delA p.(Gly469Valfs*84) +
c.2011C>T p.(Arg671Cys)
Frameshift +
Missense
aCoenen et al., 2004.
bAntonicka et al., 2006.
cValente et al., 2007.
dSmits et al., 2011.
eBalasubramaniam et al., 2012.
fGalmiche et al., 2012.
gCalvo et al., 2012.
hthis report.
All mutations named according to reference NM_024996.5.
different tissues from a patient withGFM1mutations (Antonicka
et al., 2006). The location of the specific mutation may affect par-
ticular functions and interactions of the protein, which may be
tissue specific. For example, Galmiche and colleagues hypothe-
sized that hepatic failure observed in some cases was particularly
associated with mutations located in the central region of the
mtEFG1 protein and those associated with encephalopathy were
located in peripheral segments of the protein (Galmiche et al.,
2012).
These concepts support previous clinical findings describ-
ing two main phenotypes, namely hepatic (Coenen et al., 2004;
Antonicka et al., 2006; Balasubramaniam et al., 2012; Galmiche
et al., 2012) and neurological (Valente et al., 2007; Smits et al.,
2011; Galmiche et al., 2012) (Table 1). In keeping with this
hypothesis, it is reasonable to suggest that the severe and exclu-
sively neurological phenotype in our patient implies that the
translation defect was most severe in the central nervous system.
The main reported causes of death have been related to
respiratory complications (secondary to neurological dysfunc-
tion) and to multisystem failure secondary to severe hepatic
dysfunction (Table 1). Despite the severity of the OXPHOS
defects in mitochondria and the similarity of the results to the
other patients, the progression of the disease appears to be more
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benign in our patient. At present, she is 5 years 6 months old
and has a severe encephalopathy, but has had no additional
episodes of acute clinical or metabolic decompensation since first
coming to medical attention at the age of 7 months. Her gen-
eral condition has stabilized, without regression, and she is able
to be fed by mouth, maintaining normal growth. The specific
functional and morphological consequences of the GFM1 muta-
tions identified may help explain the particular clinical course
observed in this case, but there are still no definitive clini-
cal, laboratory, radiological or genetic characteristics that could
be helpful in predicting disease severity and prognosis in this
condition.
Our understanding of the mitochondrial translation appara-
tus is increasing as more proteins are being identified in the
pathways of mitochondrial gene expression, but these type of
disorders remain without gene-specific treatment, much less a
cure (Ribas et al., 2014; Soiferman et al., 2014; Szeto, 2014). Cur-
rent investigations have evaluated the effect of small molecules
- largely through the activation of the PGC1α pathway to
stimulate mitochondrial biogenesis and consequently ATP syn-
thesis - on improving mitochondrial function in fibroblasts
of patients with combined respiratory complex disorders har-
boring known mutations in various nuclear-encoded compo-
nents of the mitochondrial translation machinery. One such
study included a patient with GFM1 mutations and showed
that the compound AICAR (5-aminoimidazole-4-carboxamide
ribonucleotide) increased complex IV activity in GFM1 cells,
demonstrating therapeutic potential (Soiferman et al., 2014).
This was one example of a specific benefit of one com-
pound in a particular cell line, but no universally benefi-
cial compound was found, highlighting the importance of
personalized medicine in mitochondrial disease (Soiferman et al.,
2014).
Concluding Remarks
Mutations in GFM1 gene are consistently associated with a com-
bined respiratory chain deficiency and persistent elevation of
blood lactate. Clinical findings are heterogeneous, but neuro-
logical and hepatic involvement are both prominent features.
Although the previously reported cases consisted of early onset,
rapidly progressive and ultimately fatal diseases, the patient
described here seems to show a more benign phenotype, though
the pathophysiology and prognosis remain unclear. To our
knowledge, this is the first patient with recessiveGFM1mutations
who has survived beyond early childhood.
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